We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas

We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas

Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well‐defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90‐7.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2017-01, Vol.123 (1), p.20-24
Hauptverfasser: Villalobos, Victor M., Hoffner, Brianna, Elias, Anthony D.
Format: Artikel
Sprache:eng
Schlagworte:
Age
Criteria
Dasatinib
Humans
Protein Kinase Inhibitors
Pyrimidines
Sarcoma
Solid tumors
Thiazoles
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well‐defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90‐7.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.30377